驾驶CAR驶向新领域：本地生产的靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗多发性骨髓瘤 - Suppr

Suppr

超能文献

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma.

作者信息

Sjöstrand Maria, Sadelain Michel

机构信息

Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Haematologica. 2023 Jul 1;108(7):1721-1723. doi: 10.3324/haematol.2022.282053.

DOI:10.3324/haematol.2022.282053

PMID:36794501

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10316265/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68b7/10316265/ef9c90e3dfbc/1081721.fig1.jpg

相似文献

Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma.驾驶CAR驶向新领域：本地生产的靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗多发性骨髓瘤

Haematologica. 2023 Jul 1;108(7):1721-1723. doi: 10.3324/haematol.2022.282053.

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。

J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.B 细胞成熟抗原是多发性骨髓瘤过继性 T 细胞治疗的一个有前途的靶点。

Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。

Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。

Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.

Chimeric Antigen Receptor T Cells in Multiple Myeloma.嵌合抗原受体 T 细胞在多发性骨髓瘤中的应用。

Hematol Oncol Clin North Am. 2023 Dec;37(6):1089-1105. doi: 10.1016/j.hoc.2023.05.008. Epub 2023 Aug 8.

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。

Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.

Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。

Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.BCMA 靶向嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。

Cancer Lett. 2023 Jan 28;553:215949. doi: 10.1016/j.canlet.2022.215949. Epub 2022 Oct 8.

[Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells].[BCMA嵌合抗原受体T细胞治疗两例髓外浸润性多发性骨髓瘤]

Zhonghua Xue Ye Xue Za Zhi. 2021 Mar 14;42(3):253-255. doi: 10.3760/cma.j.issn.0253-2727.2021.03.013.

引用本文的文献

Cancer immunotherapy and its facilitation by nanomedicine.癌症免疫疗法及其纳米医学促进作用。

Biomark Res. 2024 Aug 3;12(1):77. doi: 10.1186/s40364-024-00625-6.

Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.对嵌合抗原受体胞外结构域激活的研究：靶向多发性骨髓瘤细胞的单域抗体的经验突出了需要针对具体情况进行优化。

Front Immunol. 2024 Apr 19;15:1389018. doi: 10.3389/fimmu.2024.1389018. eCollection 2024.

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.多发性骨髓瘤的免疫治疗：当下现状预示未来发展。

Int J Mol Sci. 2023 Oct 27;24(21):15674. doi: 10.3390/ijms242115674.

Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.新型 SPEA 超级抗原肽激动剂和肽激动剂-TGFαL3 缀合物。靶向癌症免疫治疗的体外生长抑制作用研究。

Int J Mol Sci. 2023 Jun 22;24(13):10507. doi: 10.3390/ijms241310507.

本文引用的文献

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.新型国产抗 BCMA CAR T 细胞的研发与生产用于治疗复发/难治性多发性骨髓瘤：I 期临床试验结果。

Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628.

HLA-independent T cell receptors for targeting tumors with low antigen density.针对低抗原密度肿瘤的 HLA 非依赖 T 细胞受体。

Nat Med. 2022 Feb;28(2):345-352. doi: 10.1038/s41591-021-01621-1. Epub 2022 Jan 13.

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.将 CAR 与嵌合共刺激受体结合可增强 T 细胞对低抗原密度的敏感性，并促进其持久性。

Sci Transl Med. 2021 Dec 8;13(623):eabh1962. doi: 10.1126/scitranslmed.abh1962.

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.一种针对复发或难治性多发性骨髓瘤的靶向 BCMA 和 CD38 的双特异性 CAR-T 细胞疗法。

J Hematol Oncol. 2021 Oct 9;14(1):161. doi: 10.1186/s13045-021-01170-7.

CAR T cells: Building on the CD19 paradigm.嵌合抗原受体 T 细胞：以 CD19 为范例。

Eur J Immunol. 2021 Sep;51(9):2151-2163. doi: 10.1002/eji.202049064. Epub 2021 Aug 2.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。

Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤中的安全性和临床疗效。

J Hematol Oncol. 2020 Dec 3;13(1):164. doi: 10.1186/s13045-020-01001-1.

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.γ-分泌酶抑制增强了 BCMA 特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中的疗效。

Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.嵌合抗原受体 T 细胞 trogocytosis 和协同杀伤调节肿瘤抗原逃逸。

Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验